Evusheld reduces risk of symptomatic COVID-19 in high-risk population
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
List view / Grid view
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
A study has shown that the majority of dermatology advisors to the FDA took payments subsequent to drug approvals.